种族和少数民族患者参与N-of-1试验:医疗保健提供者和患者的观点

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2021-07-01 Epub Date: 2021-05-28 DOI:10.2217/pme-2020-0166
Lyndonna Marrast, Joseph Conigliaro, Camille Chan, Eun Ji Kim, Joan Duer-Hefele, Michael A Diefenbach, Karina W Davidson
{"title":"种族和少数民族患者参与N-of-1试验:医疗保健提供者和患者的观点","authors":"Lyndonna Marrast,&nbsp;Joseph Conigliaro,&nbsp;Camille Chan,&nbsp;Eun Ji Kim,&nbsp;Joan Duer-Hefele,&nbsp;Michael A Diefenbach,&nbsp;Karina W Davidson","doi":"10.2217/pme-2020-0166","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Patients from racial and ethnic minority backgrounds in the USA have historically been under-represented in research trials. Understanding their viewpoints regarding participation in N-of-1 trials is imperative as we design and implement these studies. <b>Materials & methods:</b> We conducted six focus groups of racial and ethnic minority patients (n = 25) and providers (n = 9). We used content analysis to identify themes. <b>Results:</b> Our results noted the importance of considering family members in N-of-1 trial recruitment and participation, patients' desire for education as a design feature, for 'lifestyle' changes as a treatment option and for use of nonevidence-based treatments in the design of future N-of-1 trials. <b>Conclusion:</b> Personalized trials have the potential to change the way we deliver primary care and improve disparities for minorities.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 4","pages":"347-359"},"PeriodicalIF":1.7000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242982/pdf/pme-18-347.pdf","citationCount":"2","resultStr":"{\"title\":\"Racial and ethnic minority patient participation in N-of-1 trials: perspectives of healthcare providers and patients.\",\"authors\":\"Lyndonna Marrast,&nbsp;Joseph Conigliaro,&nbsp;Camille Chan,&nbsp;Eun Ji Kim,&nbsp;Joan Duer-Hefele,&nbsp;Michael A Diefenbach,&nbsp;Karina W Davidson\",\"doi\":\"10.2217/pme-2020-0166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Patients from racial and ethnic minority backgrounds in the USA have historically been under-represented in research trials. Understanding their viewpoints regarding participation in N-of-1 trials is imperative as we design and implement these studies. <b>Materials & methods:</b> We conducted six focus groups of racial and ethnic minority patients (n = 25) and providers (n = 9). We used content analysis to identify themes. <b>Results:</b> Our results noted the importance of considering family members in N-of-1 trial recruitment and participation, patients' desire for education as a design feature, for 'lifestyle' changes as a treatment option and for use of nonevidence-based treatments in the design of future N-of-1 trials. <b>Conclusion:</b> Personalized trials have the potential to change the way we deliver primary care and improve disparities for minorities.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"18 4\",\"pages\":\"347-359\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242982/pdf/pme-18-347.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2020-0166\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/5/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2020-0166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

摘要

目的:美国种族和少数民族背景的患者历来在研究试验中代表性不足。在我们设计和实施这些研究时,了解他们对参与N-of-1试验的看法是必不可少的。材料与方法:我们对种族和少数民族患者(n = 25)和提供者(n = 9)进行了六个焦点小组。我们使用内容分析来确定主题。结果:我们的结果指出了在N-of-1试验的招募和参与中考虑家庭成员的重要性,将患者对教育的渴望作为设计特征,将“生活方式”改变作为治疗选择,以及在未来N-of-1试验的设计中使用非循证治疗。结论:个性化试验有可能改变我们提供初级保健的方式,并改善少数群体的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Racial and ethnic minority patient participation in N-of-1 trials: perspectives of healthcare providers and patients.

Aim: Patients from racial and ethnic minority backgrounds in the USA have historically been under-represented in research trials. Understanding their viewpoints regarding participation in N-of-1 trials is imperative as we design and implement these studies. Materials & methods: We conducted six focus groups of racial and ethnic minority patients (n = 25) and providers (n = 9). We used content analysis to identify themes. Results: Our results noted the importance of considering family members in N-of-1 trial recruitment and participation, patients' desire for education as a design feature, for 'lifestyle' changes as a treatment option and for use of nonevidence-based treatments in the design of future N-of-1 trials. Conclusion: Personalized trials have the potential to change the way we deliver primary care and improve disparities for minorities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1